Company intelligence / Profile preview
Braeburn Pharmaceuticals
Plymouth Meeting, Pennsylvania, United Statesbraeburnrx.com ↗
- Ownership
- Public · BBRX
- Development stage
- Other
01
Overview
FDA approved Brixadi (buprenorphine) extended-release subcutaneous injection for moderate to severe opioid use disorder in May 2023. Previously completed Phase 3 trials for CAM2038 (now Brixadi) showing positive safety and efficacy results.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Long-acting injectable and implantable formulations
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Camurus (for CAM2038/Brixadi development)Endo Pharmaceuticals (acquired risperidone implant technology)
04
Financials
- Market cap
- $439M
- Total revenue
- $65.1M
- Enterprise value
- $134.3M
Beyond the preview
Go deeper on Braeburn Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Braeburn Pharmaceuticals.